Policy & Regulation
Completion of Pre-clinical Safety Studies of MIV-818 Enables Initiation of Clinical Studies
11 January 2018 - - Stockholm, Sweden-based pharmaceutical company Medivir AB (NASDAQ Stockholm: MVIR) has completed the pre-clinical safety studies for MIV-818, enabling the start of phase I clinical trials in 2018, the company said.
MIV-818 is Medivir's proprietary liver-targeted nucleotide prodrug for the treatment of hepatocellular carcinoma (HCC) and other forms of liver cancer.
It is the first development project to emerge from Medivir's in-house drug discovery efforts in oncology.
With the successful completion of the pre-clinical safety studies on MIV-818, Medivir intends to make the necessary regulatory submissions during the first half of 2018, and to start the first clinical trials of MIV-818 during the second half of 2018.
MIV-818 has the potential to become the first liver-targeted, orally administered drug to address HCC and other forms of liver cancer.
Medivir AB is a research-based pharmaceutical company with a focus on oncology. The company speicalizes in protease inhibitor design and nucleotide/nucleoside science and is dedicated to developing innovative pharmaceuticals that meet unmet medical needs.


Related Headlines